About Ablynx
Ablynx is a company based in Ghent (Belgium) founded in 2001 was acquired by Sanofi in January 2018. Ablynx has raised $86.33 million across 11 funding rounds from investors including Sanofi, Kbc and Gimv. Ablynx operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Ghent, Belgium
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ablynx
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ablynx
Ablynx has successfully raised a total of $86.33M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $82.67 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ablynx
Ablynx has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Sanofi, Kbc and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for Ablynx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ablynx
Investment portfolio details for Ablynx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ablynx
Detailed financials for Ablynx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ablynx Comparisons
Peer comparison for Ablynx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ablynx
Ablynx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Ablynx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ablynx
Complete news archive for Ablynx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ablynx
Ablynx was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Ablynx is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Ablynx is a funded company, having raised a total of $86.33M across 11 funding rounds to date.
Founded in 2001 in Ghent, Belgium, operations in the biopharmaceutical sector are focused on the discovery and development of Nanobodies, which are single-domain antibody fragments used as therapeutic proteins. These are targeted at conditions such as inflammation, hematology, oncology, and pulmonary diseases. Approximately 45 proprietary and partnered projects are maintained in the pipeline, with five Nanobodies currently in clinical development.
Ablynx's top competitors include Merck, Roivant Sciences and AbbVie.
Ablynx has 13 investors. Key investors include Sanofi, Kbc, Gimv, VIB, and Abingworth.